An organic electroluminescence device includes a first electrode, a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one of the plurality of organic layers includes an amine compound, the amine compound includes a central nitrogen atom, a carbazole group substituted to the central nitrogen atom, and a dibenzoselenophene group substituted to the central nitrogen atom, and a nitrogen atom of the carbazole group is substituted with a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. The organic electroluminescence device thereby has high efficiency and long-life.

An organic electroluminescence device includes a first electrode, a second electrode facing the first electrode, and a plurality of organic layers between the first electrode and the second electrode, wherein at least one of the plurality of organic layers includes an amine compound, the amine compound includes a central nitrogen atom, a carbazole group substituted to the central nitrogen atom, and a dibenzoselenophene group substituted to the central nitrogen atom, and a nitrogen atom of the carbazole group is substituted with a substituted or unsubstituted aryl group or a substituted or unsubstituted heteroaryl group. The organic electroluminescence device thereby has high efficiency and long-life.

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

A compound of formula (I), wherein Ar.sup.1, R.sup.21, R.sup.23, R.sup.24, R.sup.25, R.sup.26, R.sup.27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

##STR00001##

A compound of formula (I), wherein Ar.sup.1, R.sup.21, R.sup.23, R.sup.24, R.sup.25, R.sup.26, R.sup.27, A, X, Y and W are as defined herein. The compounds of the present invention are inhibitors of hematopoietic prostaglandin D synthase (H-PGDS) and can be useful in the treatment of Duchenne muscular dystrophy. Accordingly, the invention is further directed to pharmaceutical compositions comprising a compound of the invention. The invention is still further directed to methods of inhibiting H-PGDS activity and treatment of disorders associated therewith using a compound of the invention or a pharmaceutical composition comprising a compound of the invention.

##STR00001##

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.

Disclosed are sulfonamide compounds with GPR17 modulating properties, which are useful for treating or preventing a variety of CNS and other diseases, in particular for preventing and treating myelinating diseases or disorders.